Kids & teens (for parents) · Indiana
Studies for children and teens in Indiana
These studies only enroll people under 18. A parent or legal guardian gives permission, and children old enough to understand are asked for their own agreement (assent).
37 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1/Phase 2
Classroom Break, Cognition, and Fitness in Elementary School Children
Purdue University
- Location
- Royal Center, IN
- Eligibility basics
- Ages 8–12
- RecruitingHealthy volunteersPhase 3
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
GlaxoSmithKline
- Location
- South Bend, IN + 46 other US sites
- Eligibility basics
- Ages 1–1
- RecruitingHealthy volunteers
Children's Viewing Behavior
SightGlass Vision, Inc.
- Location
- Bloomington, IN
- Eligibility basics
- Ages 7–14
- RecruitingPhase 3
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
Hoffmann-La Roche
- Location
- Mishawaka, IN + 10 other US sites
- Eligibility basics
- Ages 1 mo–11
- RecruitingPhase 3
A Study of Sepiapterin in Participants With Phenylketonuria (PKU)
PTC Therapeutics
- Location
- Indianapolis, IN
- Eligibility basics
- Up to age 9
- RecruitingPhase 3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
AbbVie
- Location
- Indianapolis, IN + 8 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 4
Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients
Fresenius Kabi
- Location
- Indianapolis, IN + 3 other US sites
- Eligibility basics
- Ages 1 mo–17
- RecruitingPhase 3
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
AbbVie
- Location
- Indianapolis, IN + 9 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
Lumos Pharma
- Location
- Indianapolis, IN + 30 other US sites
- Eligibility basics
- Ages 3–11
- RecruitingPhase 2
A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)
Pfizer
- Location
- Indianapolis, IN + 10 other US sites
- Eligibility basics
- Up to age 10 mo
- RecruitingPhase 3
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Pfizer
- Location
- Indianapolis, IN + 18 other US sites
- Eligibility basics
- Ages 6–14
- RecruitingPhase 3
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
AstraZeneca
- Location
- Indianapolis, IN + 70 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Pfizer
- Location
- Indianapolis, IN + 6 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 3
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
AbbVie
- Location
- Evansville, IN + 28 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Eli Lilly and Company
- Location
- Indianapolis, IN + 10 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Hoffmann-La Roche
- Location
- Indianapolis, IN + 8 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
AbbVie
- Location
- Newburgh, IN + 25 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
Pfizer
- Location
- Indianapolis, IN + 12 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pfizer
- Location
- Westfield, IN + 69 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Pfizer
- Location
- Westfield, IN + 54 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
Neurocrine Switzerland GmbH
- Location
- Indianapolis, IN + 10 other US sites
- Eligibility basics
- Ages 4 mo–3
- RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Incyte Corporation
- Location
- Indianapolis, IN + 65 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 2
Study of Resmetirom in Children and Adolescents With MASH
Madrigal Pharmaceuticals, Inc.
- Location
- Indianapolis, IN
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)
Takeda
- Location
- Indianapolis, IN + 9 other US sites
- Eligibility basics
- Up to age 17